Alimta News and Research

RSS
New clinical research findings on oncology to be highlighted at ASCO 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

Updated NCCN Guidelines include maintenance therapy for patients with metastatic disease

Updated NCCN Guidelines include maintenance therapy for patients with metastatic disease

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

IntrinsiQ's first IntelliView 360 research study results released

IntrinsiQ's first IntelliView 360 research study results released

FDA approves Alimta (pemetrexed) for advanced lung cancer

FDA approves Alimta (pemetrexed) for advanced lung cancer

Updated guidelines for ovarian cancer

Updated guidelines for ovarian cancer

New clinical trial for patients with asbestos-associated lung cancer

New clinical trial for patients with asbestos-associated lung cancer

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

Studies try to shed light on impact of race

Studies try to shed light on impact of race

Britain second rate when it comes to treating cancer sufferers

Britain second rate when it comes to treating cancer sufferers

New data show Enzastaurin's activity across multiple cancer cell lines

New data show Enzastaurin's activity across multiple cancer cell lines

Alimta approved as first treatment for Mesothelioma, a deadly cancer caused by asbestos

Alimta approved as first treatment for Mesothelioma, a deadly cancer caused by asbestos